Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Acquisitions (2022 - 2023)

Historic Acquisitions for Zevra Therapeutics (ZVRA) over the last 2 years, with Q4 2023 value amounting to $30.4 million.

  • Zevra Therapeutics' Acquisitions changed N/A to $30.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $44.5 million, marking a year-over-year increase of 21597.89%. This contributed to the annual value of $30.4 million for FY2023, which is 11576.3% up from last year.
  • According to the latest figures from Q4 2023, Zevra Therapeutics' Acquisitions is $30.4 million.
  • Zevra Therapeutics' Acquisitions' 5-year high stood at $30.4 million during Q4 2023, with a 5-year trough of $14.1 million in Q3 2022.